The authors used LNCaP and PC3 prostate cancer cell lines to show that chemical or shRNA-mediated inhibition of ASCT2 function in vitro decreases l-glutamine uptake; cell cycle progression through E2F transcription factors; mTORC1 pathway activation, and cell growth [257]. This evidence concerns the gene SLC1A5 and prostate carcinoma.